LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
AUSTIN, Texas, May 16, 2017 -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that management will be presenting at the UBS 2017 Global Healthcare Conference in New York on Tuesday, May 23 at 1:00 p.m. ET.
To access the live and archived webcast of the presentation, please visit the Investor Relations section of the Aeglea BioTherapeutics website. The webcast and presentation will be archived for viewing for 90 days thereafter.
About Aeglea BioTherapeutics
Aeglea is a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer. The company’s engineered human enzymes are designed to modulate the extremes of amino acid metabolism in the blood to reduce toxic levels of amino acids in inborn errors of metabolism or target tumor metabolism for cancer treatment. AEB1102, Aeglea’s lead product candidate, is currently being studied in two ongoing Phase 1 clinical trials in patients with advanced solid tumors and acute myeloid leukemia/myelodysplastic syndrome (AML/MDS). Additionally, Aeglea is recruiting patients into its ongoing Phase 1/2 trial of AEB1102 for the treatment of patients with Arginase I deficiency. The company is building a pipeline of additional product candidates targeting key amino acids, including AEB4104, which degrades homocystine, a target for an inborn error of metabolism, as well as two potential treatments for cancer, AEB3103, which degrades cysteine, and its oxidized form cystine, and AEB2109, which degrades methionine.
For more information, please visit http://aegleabio.com.
Media Contact: Kelly Boothe, Ph.D. Pure Communications 415.946.1076 [email protected] Investor Contact: Charles N. York II Chief Financial Officer Aeglea BioTherapeutics [email protected]
